Latest News

Cellectricon strengthens its expertise in neurodegenerative diseases by the appointment of new Scientific Advisory Board member Professor Henrik Zetterberg

Cellectricon, a collaborative services provider dedicated to advance drug discovery and research in the areas of chronic pain and CNS disease, has appointed Professor Henrik Zetterberg to its scientific advisory board. Professor Zetterberg brings extensive expertise in Alzheimer’s disease and other neurodegenerative brain disorders.

Professor Zetterberg, MD, PhD, is Professor of Neurochemistry at the University of Gothenburg, Sweden, and at University College London, UK, as well as the Head of the Department of Psychiatry and Neurochemistry at the Sahlgrenska Academy at the University of Gothenburg, Sweden. With a background in molecular biology and medicine, Professor Zetterberg has spent the past 10 years focusing on the development of biomarkers for Alzheimer’s disease and other brain disorders. His research involves evaluation of biomarkers in cell and animal models, as well as in longitudinal studies of patients and healthy individuals. He has published more than 900 scientific articles and has received the Erik K. Fernström prize for young scientists, the Inga Sandeborg prize for research on Alzheimer’s disease and the Parkinson Research Foundation Research Award.

“Cellectricon has a strong track record of developing innovative in vitro assays for early stage Pain and CNS drug discovery” said Professor Zetterberg. “I am pleased to join its Scientific Advisory Board and look forward to helping the company to further develop and apply its unique drug discovery platform in the context of Alzheimer’s disease and other neurodegenerative disorders.”

“We are very pleased to welcome Henrik to our Scientific Advisory Board, where he will bring extensive disease area knowledge which nicely complements the skill sets of our other board members” said Cellectricon’s CEO, Dr Mattias Karlsson. “Professor Zetterberg will be a key contributor in supporting our upcoming launch of a groundbreaking services offering targeting Alzheimer’s and other neurodegenerative disorders. Also, we are confident he will provide valuable scientific support to our ongoing projects.”

The partnership promises to further advance Cellectricon’s CNS Discovery Services, and to give clients access to the company’s unique drug discovery platform for neurodegenerative disease-related projects.

For more information on Cellectricon’s Pain and CNS Discovery Services, please visit the Discovery Services Page.